Application value of combined detection of serum chitinase-3-like protein 1, carcino-embryonic antigen and carbohydrate antigen 15-3 in diagnosing breast cancer
SHI Wei, JIANG Yan, TAN Li-ming, WU Yi, LI Cun-yan
The People’s Hospital of Hunan Province, Changsha, Hunan 410002, China
Abstract：Objective To explore the clinical application values of serum chitinase-3-like protein 1(CHI3L1),carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3) detection used alone or in combination for thediagnosis of breast cancer. Methods Eighty-eight patients with breast cancer, 40 patients with benign breast diseases and 30 physical examinees were selected as the research subjects. Quantitative enzyme-linked immunosorbent assay was used to detect the serum level of CHI3L1, and chemiluminescence assay to detect the serum levels of CEA and CA15-3. Receiver operating characteristic (ROC) curve was employed to assess the application values of the above-mentioned indexes applied alone or in combination for the diagnosis of breast cancer. Results As for the breast cancer groups based on tumor size, the serum CHI3L1 level was significantly higher in the T3+T4 group than in the T1+T2 group, showing a statistically significant difference (P<0.05). The serum CHI3L1 level was significantly higher in the group with distant metastasis than in the group without distant metastasis, showing a statistically significant difference (P<0.05). The serum levels of CHI3L1, CEA and CA15-3 were significantly higher in the breast cancer group than in the benign breast disease group as well as the control group, with statistically significant differences (P=0.000). The area under ROC curve (AUC) of detection of CHI3L1, CEA and CA153 used alone was 0.879, 0.708 and 0.778, respectively. The AUC of combined detection of CHI3L1, CEA and CA153 was 0.956, which was significantly higher than the AUC of detection of CHI3L1, CEA and CA153 used alone. Conclusions The combined detection of serum CHI3L1, CEA and CA15-3 has important reference value for the diagnosis of breast cancer; moreover, it improves the diagnostic efficiency of breast cancer.
史苇, 蒋琰, 谭黎明, 吴意, 黎村艳. CH3L1、CEA及CA15-3联合检测在乳腺癌诊断中的应用价值[J]. 实用预防医学, 2020, 27(8): 930-933.
SHI Wei, JIANG Yan, TAN Li-ming, WU Yi, LI Cun-yan. Application value of combined detection of serum chitinase-3-like protein 1, carcino-embryonic antigen and carbohydrate antigen 15-3 in diagnosing breast cancer. , 2020, 27(8): 930-933.
[1] Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2017,3(4):524-548. [2] 张宗美,赵岭,王义亮,等.超声弹性成像、彩色多普勒超声与钼靶X线在乳腺疾病诊断中的价值[J].重庆医学,2013,42(30):3604-3605,3609. [3] 万军. 血清肿瘤标志物CA15-3,CA125,CEA和HER-2联合检测在乳腺癌诊断中的价值[J]. 现代检验医学杂志, 2018, 33(6):119-121. [4] Gao J, Zhang Q, Xu J, et al. Clinical significance of serum miR-21 in breast cancer compared with CA15-3 and CEA[J]. Chinese J Cancer Res, 2013(6):135-140. [5] Grajo JR, Barr RG. Strain elastography for prediction of breast CAncer tumor grades[J]. J Ultrasound Med, 2014, 33(1):29-34. [6] Bozkurt M, Yumruae AI. Evaluation of the importance of the serum levels of CA125,CA15-3,CA199,carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy[J]. Eur J Gynaecol Oncol, 2013, 34(6):540-544. [7] Hu B,Trinh K,Figueira WF, et al. Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family[J]. J Biol Chem,1996,271:19415-19420. [8] Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer[J]. Dan Med Bull,2006,53:172-209. [9] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2017版)[J].中国癌症杂志,2017,27(9):695-759. [10] Edge SB,Byrd DR,Compton CC,et al. AJCC cancer staging manual[M]. 7th ed. New York: Springer,2010:347-346. [11] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. [12] Chen XL,Chen XY.Significance of serum tumor marker in the diagnosis of lung cancer[J].J Clin Lung,2004,9(6):590-592. [13] 冯万锐,苗立群.乳腺癌患者血清肿瘤标志物的变化及意义[J].临床医学研究与实践,2018,3(8):66-67. [14] Watanabe H,Okada M,Kaji Y,et al. New response evaluation criteria in solid tumours-revised RECIST guideline(version 1.1)[J]. Gan To Kagaku Ryoho,2009,36(13):2495-2501. [15] Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update[J]. J Clin Oncol, 2013, 31(7):961-965. [16] Di Gioia D,Heinemann V,Nagel D,et al. Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer(MBC)[J]. Tumour Biol,2011,32(4):777-785. [17] 司先科,李炜,于昆,等.人几丁质酶-3样蛋白-1在人胃癌细胞中的表达及其对人胃癌细胞增殖和侵袭能力的影响研究[J].上海医药,2018,39(21):62-65. [18] 陈敏, 赖天文, 招轩娜. CHI3L1基因多态性和血清YKL-40水平与支气管哮喘发病的关联性[J]. 吉林大学学报, 2014,40(5):1058 -1063. [19] 巩祖顺. 动脉粥样硬化中几丁质酶3样蛋白1的组织学表达及干预研究[D]. 济南:山东大学,2014. [20] Prakash M,Bodas M,Prakash D, et al. Diverse pathological implications of YKL-40: answers may lie in ‘outside-in’ signaling[J]. Cell Signal,2013,25:1567-1573. [21] Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker[J]. Future Oncol,2009,5:1065-1082. [22] 毛玉环,谭黎明,李建英,等.血清壳多糖酶3样蛋白1和甲胎蛋白及铁蛋白检测在原发性肝癌诊断中的应用评价[J].实用预防医学,2018,25(4):401-404.
2020, Vol. 27 
